Originally published as JCO Early Release 10.1200/JCO.2007.11.2854 on June 25 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Du, Y. Articles by Ell, P. J. Search for Related Content PubMed PubMed Citation Articles by Du, Y. Articles by Ell, P. J.

Fusion of Metabolic Function and Morphology: Sequential [¹⁸F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer

Yong Du, Ian Cullum, Tim M. Illidge, Peter J. Ell

From the Institute of Nuclear Medicine, University College London Hospitals National Health Service Foundation Trust, and University College London, London; and the Cancer and Imaging School, University of Manchester and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom

Address reprint requests to Yong Du, MD, PhD, Institute of Nuclear Medicine, 5th Floor, University College Hospital, 235 Euston Rd, London NW1 2BU, United Kingdom; e-mail: yong.du{at}uclh.nhs.uk

Purpose: By monitoring bone metastases with sequential [¹⁸F]fluorodeoxyglucose positron-emission tomography/computed tomography ([¹⁸F]FDG-PET/CT) imaging, this study investigates the clinical relevance of [¹⁸F]FDG uptake features of bone metastases with various radiographic appearances.

Patients and Methods: Bone metastases were found in 67 of 408 consecutive patients with known/suspected recurrent breast cancer on [¹⁸F]FDG-PET/CT, characterized by CT morphology changes and/or bony [¹⁸F]FDG uptake. Twenty-five of the patients had sequential [¹⁸F]FDG-PET/CT examinations (86 studies) over an average follow-up period of 23 months. The temporal changes in [¹⁸F]FDG uptake and corresponding CT morphology features of 146 bone lesions identified in these 25 patients were followed up and correlated with therapeutic outcome retrospectively.

Results: The 146 lesions were classified as osteolytic (77), osteoblastic (41), mixed-pattern (11), or no change/negative (17) on CT. The majority of the osteolytic (72; 93.5%) and mixed-pattern lesions (nine; 81.8%), but fewer of the osteoblastic lesions (25; 61%), showed increased [¹⁸F]FDG uptake. After treatment, 58 osteolytic lesions (80.5%) became [¹⁸F]FDG negative and osteoblastic on CT and only 14 relatively large lesions (19.5%) remained [¹⁸F]FDG avid. Of the 25 [¹⁸F]FDG-avid osteoblastic lesions, 13 (52%) became [¹⁸F]FDG negative, but 12 (48%) remained [¹⁸F]FDG avid and increased in size on CT. Five of the mixed-pattern lesions remained [¹⁸F]FDG avid after treatment. All 17 CT-negative lesions became [¹⁸F]FDG negative; however, nine of them became osteoblastic. None of the initially [¹⁸F]FDG-negative lesions showed [¹⁸F]FDG avidity during follow-up.

Conclusion: [¹⁸F]FDG uptake reflects the immediate tumor activity of bone metastases, whereas the radiographic morphology changes vary greatly with time among patients.

Supported by the United Kingdom Department of Health's National Institute of Health Research Biomedical Research Centres funding scheme (to University College London Hospitals/University College London).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

published online ahead of print at www.jco.org on June 25, 2007.